Brexpiprazole for schizophrenia and as adjunct for major depressive disorder

Brexpiprazole: Package Insert

Pyrls on Instagram: Brexpiprazole's (REXULTI) new indication makes it the first FDA-approved option for agitation associated with dementia due to Alzheimer's disease ✨ Learn more about brexpiprazole in your Pyrls app or

Aripiprazole, brexpiprazole, and cariprazine: Not all the same

Treatment Discontinuation Among Patients with Schizophrenia Treated with Brexpiprazole and Other Oral Atypical Antipsychotics in Japan: A Retrospective Observational Study

Brexpiprazole: A Newly Approved Atypical Antipsychotic Agent

Refining Your Treatment Options for Major Depressive Disorder (MDD)

REXULTI® (brexpiprazole), MDD

Brexpiprazole Semantic Scholar

Biomedicines, Free Full-Text

Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data - ScienceDirect

Table 1 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

PDF) The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and asadjunctive treatment in patients with major depressive disorder: An analysis of short-term and long-term studies

Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: Post hoc analysis of Inventory of Depressive Symptomatology Self-Report data - ScienceDirect

Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies - ScienceDirect